AVITA Medical, Inc. (AVHHL)
| Market Cap | 118.01M |
| Revenue (ttm) | 74.88M |
| Net Income (ttm) | -51.57M |
| Shares Out | n/a |
| EPS (ttm) | -1.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 225 |
| Average Volume | 25,048 |
| Open | 1.115 |
| Previous Close | 1.250 |
| Day's Range | 1.115 - 1.115 |
| 52-Week Range | 0.751 - 2.665 |
| Beta | 1.64 |
| RSI | 46.18 |
| Earnings Date | Nov 6, 2025 |
About AVITA Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi... [Read more]
Financial Performance
In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.
Financial StatementsNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. ("Avita" or the "Company") (NASDAQ: RCEL). Such investors are advised to co...
AVITA Medical (RCEL) Shares Plummet as Interim CEO Appointed
AVITA Medical (RCEL) Shares Plummet as Interim CEO Appointed
RCEL: Lake Street Downgrades AVITA Medical to Hold, PT Slashed by 50% | RCEL Stock News
RCEL: Lake Street Downgrades AVITA Medical to Hold, PT Slashed by 50% | RCEL Stock News
Avita Medical (RCEL) Forecasts $17 Million in Q3 Revenue
Avita Medical (RCEL) Forecasts $17 Million in Q3 Revenue
AVITA Medical (RCEL) Appoints Interim CEO and Updates Revenue Guidance
AVITA Medical (RCEL) Appoints Interim CEO and Updates Revenue Guidance
AVITA Medical Appoints Cary Vance As Interim CEO
(RTTNews) - AVITA Medical Inc. (RCEL, AVH.AX) announced that it has appointed Chairman of the Board Cary Vance as Interim Chief Executive Officer, effective immediately. In conjunction with this appoi...
AVITA Medical Announces CEO Transition
VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced th...
AVITA MEDICAL INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options If you purchased or acquired ...
AVITA REMINDER: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders
Avita revealed a six-month backlog of unpaid Recell claims due to CMS pricing delays, hurting demand and driving shares down 21% to $4.25 on August 8, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. ("Avita" or the "Company") (NASDAQ: RCEL). Such investors are advised to con...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. ("Avita" or the "Company") (NASDAQ: RCEL). Such investors are advised to co...
AVITA (RCEL) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into AVITA Medical, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options If you purchased or acquired ...
AVITA Medical (RCEL) Secures NTAP Reimbursement for RECELL
AVITA Medical (RCEL) Secures NTAP Reimbursement for RECELL
CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds
Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases...
Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL) on behalf of investors con...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. ("Avita" or the "Company") (NASDAQ: RCEL).
AVITA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options If you purchased or acquired s...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL). Such investors are advised...
AVITA Medical: Reimbursement Reset And Breakeven Path By 2026
AVITA Medical is building a full-thickness wound workflow. They have the RECELL/RECELL GO, Cohealyx, and PermeaDerm. As a whole, this gives them a holistic platform solution for better clinical integr...
AVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options If you purchased or acquired s...
Avita Medical (RCEL) Stock Surges 35% Following CE Certification
Avita Medical (RCEL) Stock Surges 35% Following CE Certification
Avita Medical (RCEL) Achieves CE Mark Approval for RECELL GO
Avita Medical (RCEL) Achieves CE Mark Approval for RECELL GO
Avita Medical stock jumps 10% after securing CE Mark for RECELL GO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. ("Avita" or the "Company") (NASDAQ: RCEL).
RCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $RCEL--RCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law Firm.